Key result
Probucol combined with telmisartan significantly reduced 24-h proteinuria levels compared with telmisartan alone in patients with type 2 diabetes over 48 weeks.
Why the study?
Does probucol combined with telmisartan reduce urinary protein levels in patients with type 2 diabetes and proteinuria compared to telmisartan alone?
RCT (n=160)
Double-blind
randomly assigned
Yes
Does probucol combined with telmisartan reduce urinary protein levels in patients with type 2 diabetes and proteinuria compared to telmisartan alone?
The addition of probucol to telmisartan significantly reduces 24-h proteinuria in patients with type 2 diabetes and diabetic nephropathy compared to telmisartan alone.
Answers are grounded in this paper and cite their sources.
Supports probucol addition to telmisartan for proteinuria reduction in type 2 diabetes; extends ARB monotherapy evidence with RCT data.
BACKGROUND: Persistent proteinuria is an important factor contributing to the progression of diabetic nephropathy. The present randomized double-blind placebo-controlled multicenter clinical study evaluated the efficacy and safety of telmisartan combined with the antioxidant probucol in reducing urinary protein levels in patients with type 2 diabetes (T2D). METHODS: Patients with T2D and 24-h proteinuria 0.5-3 g were enrolled in the study and randomly assigned to one of two groups: a telmisartan or a probucol + telmisartan group. Both groups were given telmisartan 80 mg q.d. for 48 weeks. The probucol + telmisartan group was given probucol 500 mg b.i.d. for the first 24 weeks, with the dosage then reduced to 250 mg b.i.d. for the remaining 24 weeks. The telmisartan group was given probucol placebo. RESULTS: In all, 160 patients were enrolled in the present study. The 24-h proteinuria levels were significantly reduced in the probucol + telmisartan compared with telmisartan group. For patients with baseline 24-h proteinuria levels <1.0 g, both treatments resulted in significant reductions in 24-h proteinuria levels after 48 weeks treatment. However, in patients with baseline 24-h proteinuria levels ≥1.0 g, 24-h proteinuria levels after 48 weeks treatment were only reduced in the probucol + telmisartan group. There was no significant difference between the two groups for either adverse cardiovascular or other events. CONCLUSIONS: In patients with diabetic nephropathy, probucol combined with telmisartan more effectively reduces urinary protein levels than telmisartan alone.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2015) conducted an RCT in Type 2 diabetes with proteinuria (n=160). Probucol + telmisartan vs. Telmisartan 80 mg q.d. + probucol placebo was evaluated on 24-h proteinuria levels. Probucol combined with telmisartan significantly reduced 24-h proteinuria levels compared with telmisartan alone in patients with type 2 diabetes over 48 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: